The role of natural killer cells in liver inflammation

A. J. Highton 1 · I. S. Schuster 2,3 · M. A. Degli-Esposti 2,3 · M. Altfeld 4

Received: 10 March 2021 / Accepted: 3 June 2021 / Published online: 7 July 2021
© The Author(s) 2021

Abstract
The liver is an important immunological site that can promote immune tolerance or activation. Natural killer (NK) cells are a major immune subset within the liver, and therefore understanding their role in liver homeostasis and inflammation is crucial. Due to their cytotoxic function, NK cells are important in the immune response against hepatotropic viral infections but are also involved in the inflammatory processes of autoimmune liver diseases and fatty liver disease. Whether NK cells primarily promote pro-inflammatory or tolerogenic responses is not known for many liver diseases. Understanding the involvement of NK cells in liver inflammation will be crucial in effective treatment and future immunotherapeutic targeting of NK cells in these disease settings. Here, we explore the role that NK cells play in inflammation of the liver in the context of viral infection, autoimmunity and fatty liver disease.

Keywords
Liver inflammation · NK cells · Viral hepatitis · Autoimmune liver disease · Fatty liver disease

Introduction
The liver is a central organ involved in digestion, metabolism and detoxification of blood. The majority of blood entering the liver comes via the hepatic portal vein from the spleen and gastrointestinal tract. This venous blood carries antigens, which are subsequently exposed to the liver immune repertoire, positioning the liver as an important immunological site for both immune tolerance and activation. Dysregulation of these immunological processes can affect both liver and systemic immune responses. The liver is home to a variety of immune cells including Kupffer cells, MAIT cells, γδ T cells, αβ T cells, B cells, NKT cells, ILCs and NK cells [1]. Among these, NK cells make up 40% of total lymphocytes in the liver of humans [2], indicating the potential for an important role for NK cells in regulating liver immunity. NK cells are important in early innate immune responses but can also regulate other innate and adaptive immune responses [3] and have been suggested to play an important role in the pathogenesis of several liver diseases, including autoimmune diseases of the liver and hepatotropic viral infections [4]. The involvement of NK cells in hepatocellular carcinoma (HCC) (reviewed in [5, 6]), though important, is beyond the scope of this review and not discussed.

NK cells can both lyse infected or cancerous cells and also produce pro-inflammatory cytokines such as interferon gamma (IFNγ). The function of NK cells is tightly regulated via signalling through both activating and inhibitory receptors expressed on their surface. In humans, inhibitory killer Ig-like receptors (KIRs) primarily bind to human leukocyte antigen (HLA)-B and HLA-C molecules, while the inhibitory receptor NKG2A binds to HLA-E [7–10] (Fig. 1). The interactions with these inhibitory NK cell receptors ensure that healthy cells expressing HLA class I molecules are not inappropriately targeted by NK cells. Activating receptors such as Nkp30, Nkp44, Nkp46 and NKG2D and activating KIRs are also expressed by NK cells and promote NK cell activation upon binding to their ligands, which include stress molecules...
and molecules upregulated in response to inflammation [11]. A combination of loss of binding of inhibitory receptors and engagement of activating receptors results in NK cell activation and can facilitate killing of virally infected cells, cancerous cells or inappropriately activated cells.

Tissue-resident populations of NK cells have been described in multiple organs with distinct phenotype and function, indicating specific interactions between these tissues and NK cells [12]. Indeed, the liver possesses a distinct population of liver-resident NK cells (lrNKs) important for the immune function of this organ, along with conventional NK cells (cNKs) (Fig. 2). While cNKs circulate through the liver and vasculature, lrNKs are believed to remain in the liver [13]. cNKs are broadly categorised based on expression of the adhesion molecule CD56 as CD56bright or CD56dim NK cells, with the latter subset being the most numerous in peripheral blood [14]. In contrast, CD56bright NK cells are largely enriched in the liver compared to the blood, with almost equal frequencies of CD56bright compared to CD56dim NK cells [15]. These CD56bright lrNKs can be further defined based on their expression of CD69, CD49a, CCR5 and CXCR6 [13]. CD69 suppresses tissue egress through association with sphingosine-1-phosphate receptor 1, and CD49a is a collagen-binding integrin, thus promoting tissue retention [16, 17]. The presence of CCL3, CCL5 and CXCL16 in liver sinusoids further promotes the retention of NK cells expressing the cognate receptors CCR5 and CXCR6 [13]. lrNKs have been shown to be not only phenotypically different from their CD56bright cNK brethren but also transcriptionally distinct [18], and as with other tissues [19], these resident NK cells

---

**Fig. 1** Activating and inhibitory receptors expressed on NK cells. NK cell-activating receptors binding to their respective ligands promote activation and subsequent cytotoxicity and cytokine production, while inhibitory receptors oppose this response. *Created with BioRender.com*

**Fig. 2** Subsets of NK cells present within the liver and vasculature. CD56bright cNK cells are located primarily within the vasculature. CD56dim cNK cells can be found within the vasculature and also in the liver parenchyma. Resident within the liver are lrNK cells expressing CCR5, CXCR3, CXCR6, CD69, CD49a and CD56. *Created with BioRender.com*
appear to be specifically suited to function in the liver environment and integral to the regulation of immune function in this organ. Here, we discuss liver NK cells and their involvement in the pathogenesis of liver inflammation and diseases following dysregulation.

**NK cells in the liver**

Liver-resident NK-like cells (NK1.1+/CD3-) were first described in the mouse and were initially distinguished from cNK cells by the absence of the mature NK cell marker CD49b and high TRAIL expression at steady state [20]. The identification of an increasing number of tissue-resident NK-like cells, not only in the liver but also in other non-lymphoid tissues, led to the introduction of a new nomenclature, which classifies most tissue-resident NK-like cells as innate lymphoid cells type 1 (ILC1) in the mouse (reviewed in Vivier et al. 2018 [21]). Although ILC1s have also been described in humans, NK cells and ILC1s are difficult to distinguish due to the lack of specific markers. For the purpose of this review, we will therefore refer to human liver-resident NK cells and ILC1s as lrNK cells. The transcription factors required for mouse liver ILC1 cell development are distinct from their cNK counterparts: murine ILC1s depend on T-bet and Hobit, while cNK cells require Eomes for their development [22–24]. Liver ILC1s have recently been reported to develop locally, with IFNγ production by liver ILC1s promoting their development from IFNγR+ liver progenitors [25]. Transfer and parabiosis studies have confirmed that hepatic ILC1s home back to the liver where they are maintained without recirculating, thus identifying them as *bona fide* tissue-resident cells [26, 27]. Further investigations revealed extensive phenotypic differences between ILC1 and cNK populations [21, 26, 27]. Figure 3 provides an overview of murine liver cNK cells and ILC1s at steady state. Unsupervised dimensional reduction analysis of NKp46+ cells in the liver (Fig. 3A) shows distinct clustering of ILC1s and cNK cells (Fig. 3B). ILC1s are distinguished as CD49a+ CD49b- cells (Fig. 3C), which lack the expression of Eomes, CD11b, CD62L and KLRG1 but express CD200R, CXCR6, CD69 and CD103, while cNK cells present with the reverse phenotype at steady state (Fig. 3D). Furthermore, unlike cNK cells, ILC1s have limited cytotoxic potential but are capable of mounting a strong cytokine response [21].

Subsequent to the characterisation in the mouse, human CD56bright CD16– lrNK cells were distinguished from hepatic cNK cells based on the expression of CD69 and the chemokine receptors CXCR6 and CCR5 [13, 18]. Expression of these receptors specifically occurs on lrNK cells, but not on cNK cells, and the chemokine receptors CCR5 and CXCR6 are thought to mediate localisation to liver sinusoids, a compartment rich in the expression of the respective ligands CCL3, CCL5 and CXCL16 [13]. CXCR6+ lrNK cells express Eomes but lack T-bet along with a number of KIR molecules [13, 18]. Functionally, CXCR6+ lrNK cells produce less IFNγ, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)-1β in response to stimulation than hepatic cNK cells. They also express less perforin and Granzyme B but show enhanced Granzyme K expression and are capable of degranulation [28]. Finally, a study investigating hepatic NK cells in liver transplants ascertained that, although CXCR6+ lrNK cells are long-lived and do not recirculate, they could still be replenished from the circulation [28]. In addition to CXCR6+ CD56bright CD16- lrNK cells, a second liver-resident NK cell population has been described [29]. These cells are CD56bright CD16-, lack CXCR6 expression and instead are identified by expression of CD49a—similar to mouse ILC1s [26, 29]. CD49a+ lrNK were present in approximately 40% of tested individuals with a frequency of approximately 2.3% of hepatic CD56bright cells. CD56bright CD49a+ NK cells specifically localised to the liver parenchyma and, unlike CXCR6+ lrNKs, expressed T-bet but not Eomes. They also exhibited a pattern of KIR and NKG2C expression indicative of clonal-like expansion, although they did not express CD57, a marker expressed on differentiated cNK cells. Furthermore, CD56bright CD49a+ lrNK cells had reduced capacity to degranulate compared to hepatic CD49a+ NK cells but were potent producers of cytokines such as IFNγ, TNF and GM-CSF.

Overall, there is compelling evidence to support that the liver harbours multiple distinct subsets of resident as well as circulating NK cells at steady state. We are only beginning to understand the roles that these NK cell subsets play in response to immunological challenges, with many questions still unanswered, such as their roles in maintaining liver homeostasis or during hepatic insults. In this regard, the phenotype, function and anatomical localisation of lrNK and hepatic cNK may provide insights about their specific roles in maintaining overall liver health. For instance, it is highly plausible that sinusoidal lrNK cells may play a role in shaping the responsiveness of other sinusoidal cells, such as Kupffer cells. Interestingly, it has been reported that murine liver ILC1s can generate antigen-specific recall responses in a model of contact hypersensitivity [26, 30]. By extension, human CD49a+ lrNK cells may therefore represent an analogous memory-like population, as they are characterised by the expression of a receptor repertoire consistent with clonal expansion [29]. However, how tissue-resident cells can induce antigen-specific responses in distal sites remains to be understood. Below, we review the roles of hepatic NK cell populations in liver homeostasis and in the context of different inflammatory settings.

**NK cells in liver homeostasis and tolerance**

The liver is continuously exposed to microorganisms, microbial products and food antigens delivered through the portal
vein from the intestine. This necessitates an increased level of immune tolerance to avoid excessive inflammation, tissue damage and loss of liver function. This immunological status is mediated by a complex interplay of hepatic cells and immune cells, including NK cells. NK cells can shape, and in turn are shaped, by the hepatic microenvironment via both direct cell-to-cell contact and the production of soluble factors. Kupffer cells are liver sinusoid-resident macrophages that play an important role in activating NK cells via the expression of interleukin (IL)-18 following the detection of microbiological products [31]. Simultaneously, Kupffer cells can also suppress NK cell activity through the production of IL-10 that leads to inhibition of IFNγ expression and renders NK cells hyporesponsive [31, 32]. In addition, the exposure of hepatic NK cells to apoptotic cells has been shown to induce transforming growth factor beta (TGF-β) expression by NK cells, which acts in an autocrine manner to reduce NK cell IFNγ production [33]. The roles of hepatic l NK and cNK cell populations in regulating liver homeostasis and tolerance are not well delineated and thus require further investigation to dissect their specific contributions. Transcriptional profile analyses of murine hepatic NK cells and ILC1s revealed increased expression of genes associated with immune regulation in resident ILC1s and an increase in genes associated with cytotoxic function in cNK cells [34]. Consistent with this, hepatic ILC1s are capable of providing protection against acute liver injury [35]. Following the initiation of liver damage, murine ILC1s are activated via IL-12 to produce IFNγ, which induces the upregulation of the antiapoptotic factor Bcl-xL in hepatocytes. These findings stand in contrast to previous

![Image](image-url)
reports linking NK cell IFNγ production to increased liver damage and impaired regeneration in models of partial hepatectomy with concomitant viral infection or toll-like receptor (TLR) 3 ligand administration [36, 37]. It is important to note that these studies did not dissect the respective roles of lrNK and cNK cells. A possible explanation for the disparate findings on the role of NK cell IFNγ production may thus be due to cytokine release by cNK cells in distinct niches within the liver, as well as concentration dependent effects of IFNγ.

**NK cells in a diseased liver**

NK cells can play a role in multiple liver diseases, including autoimmune diseases of the liver, cancer, fatty liver disease and viral diseases. The impact of NK cells on liver diseases is mediated through their direct cytotoxic function against hepatocytes, cholangiocytes or other immune cells in the liver, including T cells and antigen-presenting cells, and the secretion of cytokines, including IFNγ (Fig. 4). NK cells can thereby either promote or reduce liver inflammation. Under normal circumstances, cytotoxic and inflammatory functions of NK cells aid in the clearance of acute disease, thus facilitating a return to homeostasis. However, persistent insults without resolution can lead to chronic liver inflammation due to dysregulation of inflammatory processes. Persistent inflammation can lead to liver fibrosis, which can ultimately progress to cirrhosis and permanent liver damage. Although acute inflammation can be helpful in restoring health, chronic inflammation is a common hallmark of multiple liver diseases.
facilitated by NK cells, along with other immune cells. The role of cNK cells in the aetiology of a number of liver diseases is discussed below.

**NK cells in autoimmune liver diseases**

Dysregulation of the liver’s immune milieu due to both genetic and environmental factors can lead to autoimmune targeting of liver-specific compartments. Three main autoimmune liver diseases have been described in the liver: primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) [38].

PBC is most prevalent in women and is typically characterised by destruction of the small intrahepatic bile ducts and production of anti-mitochondrial antibodies [40]. Both circulating and liver NK cell frequencies are increased in PBC patients, as is the cytotoxic function of NK cells [39, 40], suggesting that NK cells may be involved in PBC pathogenesis. Indeed, biliary epithelial cells (BECs) have been shown to be destroyed by autologous NK cells at a high NK:BEC ratio [41]. Interestingly, at a low NK:BEC ratio, NK cells protect BECs from subsequent destruction by NK cells via IFNγ-mediated upregulation of HLA, though this renders the BECs susceptible to killing by autoreactive T cells [41], again suggesting that NK cells can promote or reduce disease progression depending on the specific circumstances. Circulating NK cells expressing CXCR6 and CD49a are found in higher frequencies in PBC patients compared to healthy controls, and low-dose IL-12 stimulation has been shown to preferentially increase expression of these markers [42], potentially linking monocyte activation to NK cell dysregulation. Together, these data suggest a propensity for liver homing of NK cells in PBC and a potential role for NK cells in lysing BECs.

PSC occurs equally in both males and females but is more often subclinical in females [38, 44]. PSC is characterised by destruction of both intra- and extra-hepatic bile ducts leading to fibrosis and diffuse inflammation [38]. The frequencies of HLA-Bw4 and HLA-C2, ligands for the inhibitory NK cell receptors KIR3DL1 and KIR2DL1, respectively, were reduced in PSC patients compared to healthy controls, indicating a potential role for NK cells in the disease [45]. PSC patients with less fibrosis were shown to have more hepatic NK cells [46], potentially due to the reported anti-fibrotic role of NK cells in the liver via killing of pro-fibrogenic hepatic stellate cells (HSCs) [47–50]. Increased CCR7 expression has been reported on circulating and intrahepatic NK cells in PSC patients [51], and plasma levels and intrahepatic expression of CCL21, the ligand for CCR7, were increased in PSC patients [51]. Moreover, CCL21 can be produced by CD11c+ cells present in the portal tracts of PSC livers [52]. Overall, these data suggest that the recruitment of CCR7-expressing NK cells may be contributing to liver inflammation in PSC patients.

AIH is a chronic liver disease that can present as either type I or type II disease [53]. These two disease types can be distinguished based on the presence of circulating autoantibodies. Anti-nuclear antibodies or anti-smooth muscle antibodies define type I disease, and anti-liver kidney microsomal type-1 or anti-liver cytosol type-1 autoantibodies define type II disease [54–57]. Type I is the most common form of the disease and occurs predominantly in females, while type II is more frequent in girls between the ages of 2 and 14 [56, 58]. In a Japanese cohort, KIR3DL1 and the cognate ligand HLA-B Bw4-80Ile were associated with AIH, while KIR3DL1/HLA-B Bw4-80Thr and KIR2DL1/HLC-C2 were associated with protection from the disease [59]. In a separate study, KIR2DS1 and HLA-C2 were associated with AIH [60]. These associations between KIR/HLA compound genotypes and AIH suggest a potential role for KIR+ NK cells in AIH pathogenesis. Furthermore, a recent study showed that a SNP in the HLA-DP beta chain is associated with the risk of developing AIH [61]. Interestingly, this susceptibility SNP tracks a subset of HLA-DP molecules that serve as ligands for the activating NK cell receptor Nkp44 [62], further supporting a role of NK cells in AIH pathogenesis. PolyI:C treatment in a mouse model of hepatitis demonstrated recruitment and activation of NK cells in the liver with partial disease abrogation following NK cell depletion [63]. The frequency of circulating CD56bright NK cells was found to be increased in untreated AIH patients prior to corticosteroid treatment [64], whereas decreased frequencies of circulating CD56dim NK cells have been observed in patients with active AIH or while in remission [65]. Interestingly, in a mouse model of AIH, CXCR3+ NK cells, similar to human CD56dim NK cells, were enriched in the liver, though both circulating and hepatic NK cells had increased cytotoxic phenotypes [65]. These data further suggest an important role for NK cells in AIH, including possible recruitment of destructive NK cells from the periphery. However, IrNK cells might also modulate the function of antigen-presenting cells or T cells in the liver and thereby reduce liver inflammation in AIH (Fig. 4). Overall, further research is required to understand the precise role of IrNK cells, and particular subpopulations of IrNK cells, in the pathogenesis of autoimmune liver diseases.

**Viral infections of the liver**

A number of viruses infect the liver; however, the most prevalent are the hepatotropic hepatitis viruses. There are 5 types of hepatitis viruses, classified as Hepatitis A to E despite these viruses being unrelated to each other [66]. Hepatitis A (HAV) and E (HEV) cause only acute infection, while hepatitis B (HBV), C (HCV) and D (HDV) can establish long-lasting chronic infections. In addition, chronic HBV and HCV infection can lead to the development of life-threatening liver
diseases, such as cirrhosis and HCC. Although vaccines are available for HAV, HBV and HDV, and HCV is treatable by direct acting anti-virals (DAAs), these viral infections continue to cause considerable morbidity and mortality and carry a significant burden of disease globally [67].

In patients with acute HBV infection, NK cells are highly activated as characterised by elevated expression of activating receptors, reduced expression of inhibitory receptors, increased IFNγ expression and enhanced ability to degranulate compared to NK cells from healthy controls [68, 69]. Importantly, this increased activation state was shown to correlate with the severity of liver damage (likely promoted by the cytolytic capacity of NK cells) as well as improved HBV control (likely via IFNγ production by NK cells) [68]. A more recent study outlined a role for activation of antibody-dependent cellular cytotoxicity (ADCC) by NK cells in responses to acute HBV infection and the generation of both cytotoxic and cytokine responses [70]. In addition to acting as direct effectors, NK cells can promote adaptive responses in a mouse model of acute HBV infection [71]. IFNγ production by hepatic CD49α+ CD49b+ cNK cells improves anti-viral CD8+ T cells responses, leading to enhanced viral clearance [71]. By contrast, during chronic HBV (CHB) infection, NK cells display fewer activating and more inhibitory receptors and lose effector functions, particularly the capacity to secrete cytokines [72, 73]. These findings are consistent with recent studies describing the expansion of dysfunctional CD56+ CD16+ NK cells and a transcriptional NK cell profile similar to that of exhausted T cells in CHB patients [74, 76]. NK cell dysfunction in CHB patients is mediated by elevated expression of immunosuppressive cytokines such as IL-10 and TGF-β [75, 76]. Blocking these cytokines increased the expression of activating receptors and improved NK cell effector function. Although CHB significantly decreases the functionality of NK cells, numerous studies have reported increased TRAIL expression on both circulating and hepatic NK cells [77–79]. CD56+ TRAIL+ NK cells can kill hepatocytes in vitro, and their presence has been associated with the severity of liver damage in patients with CHB-related liver cirrhosis [77, 78]. Furthermore, TRAIL+ NK cells have been shown to induce apoptosis of HBV-specific CD8+ T cells, which would thereby lead to impaired virus control and increased immunopathology. Thus, TRAIL+ NK cells can mediate both liver damage (by killing hepatocytes) and impair anti-viral responses (by killing anti-viral T cells) [79].

Similar to HBV, NK cells are involved in the response to HCV infection. Although the availability of DAAs has significantly improved the outcome of HCV infection, HCV-induced pathologies still pose a major health burden [67], and understanding the role of the immune response to HCV remains highly relevant. Genetic analyses have provided evidence for associations between the expression of specific KIRs and their HLA ligands and the outcome of HVC infection. This is best exemplified by the finding that the KIR2DL3/HLA-C1/C1 genotype is associated with spontaneous resolution of HCV infection [80]. Furthermore, in culture systems, KIR3DS1+ NK cells have been shown to recognise and lyse HCV-infected hepatocytes expressing HLA-F and have therefore been postulated to assist in controlling HCV infection [81]. The role of NK cells during acute HCV infection is clear, but the relevant mechanisms remain largely unknown. Although NK cells from infected subjects have been reported to have an enhanced capacity to secrete IFNγ and degranulate compared to those from uninfected controls, these activities do not appear to correlate with the outcome of infection [82]. Interestingly, a recent study has shown that NK cells activated by cytokines present during HCV infection can kill CD4+ T cells and has proposed that this may actually promote progression to chronicity [83]. In patients with chronic HCV (CHC) infection, the distribution of NK cell subsets is altered, and there is a relative increase in CD56bright NK cells compared with healthy controls [84, 85]. Furthermore, NK cells display both phenotypic and functional changes. Despite some inconsistencies between different studies, increased expression of activating receptors, such as NKG2D and NKP44, has been reported in NK cells from CHC patients compared to those from healthy controls [73, 86]. A polarisation in NK cell functionality, manifesting as reduced capacity to express IFNγ and TNF but increased degranulation, indicative of greater cytotoxic potential, was noted in CHC patients [86]. This phenotype was attributed to exposure to IFNαx as recapitulated by exposing NK cells to this cytokine in vitro [86]. In separate studies, CHC infection was associated with a decrease in NK cell effector function, a phenotype linked to increased expression of the inhibitory receptor CD94/NKG2A [87, 88]. NK cells from CHC patients exhibited higher CD94/NKG2A expression and produced elevated levels of IL-10 and TGF-β when cultured with hepatocytes expressing HLA-E, the CD94/NKG2A cognate ligand [87]. Blocking NKG2A signalling resulted in reduced IL-10 and TGF-β production by NK cells and restored the ability of NK cells to participate in the activation of DC required to prime anti-viral T cell responses [87]. A more recent study, using a humanised mouse model, confirmed that impaired NK cell function contributes to HCV persistence and that blocking NKG2A signalling can revive NK cell IFNγ secretion and improve NK cell cytotoxicity [88]. This increase in IFNγ production led to improved anti-viral CD8+ T cell responses and reduced HCV loads. Importantly, chronic HCV infection appears to permanently affect the functionality of NK cells, as the NK cell repertoire remained altered even after successful DAA treatment [89]. How this may affect NK cell responses to other immunological challenges is unknown. The respective roles of IrNK versus circulating NK cells in the response to CHC infection are not well understood. Some insight has been provided by a recent study reporting that CHC patients with lower liver disease scores showed an expansion of
hepatic CD56bright CD16− NK cells, a population thought to be resident in the liver [28, 90]. Expansion of CD56bright CD16− IrNK cells also correlated with increased levels of IL-10 in portal vein blood and reduced responsiveness of hepatic lymphocytes to TLR stimulation, compared to circulating lymphocytes [90]. These findings suggest that IrNK cells may be involved in maintaining liver homeostasis in CHC. Overall, it is evident that NK cells play an important role in the immune response to both acute and chronic HBV and HCV infection. Activated NK cells can participate in elimination of virally infected cells and regulation of anti-viral responses, as well as maintenance of liver homeostasis, particularly in the acute stages of infection. Thus, dysregulated NK cell responses are often characterised by diminished effector responses and an inhibitory phenotype allowing for viral persistence and enhance tissue damage. Further studies are required to determine not only which type of NK cell responses are required for optimal viral control at different stages of infection but also the distinct roles that tissue-resident and circulating NK cells play in these processes.

In some instances, viral hepatitis can be caused by members of the herpesviridae family, such as cytomegalovirus (CMV) [91]. Although CMV hepatitis is rare in immunocompetent hosts, the virus can cause severe disease in immunocompromised individuals. Acute CMV infection is usually controlled without causing disease, but the virus remains lifelong in a state of latency, and intermittent CMV reactivation occurs but is controlled by the immune system [91]. Immune responses to CMV have been widely studied using mouse models of infection with murine CMV (MCMV). These models have provided extensive insight into the role of NK cells in the immune response to MCMV infection in the liver. Following acute infection, NK cells are recruited into the liver where they contribute to the control of MCMV through cyto-toxic and cytokine (mainly IFNγ) responses [92, 93]. During infection, NK cells also play a critical role in regulating macrophage activation in a perforin-dependent manner [94]. In the absence of NK cell-mediated regulation, excessive TNF production by macrophages leads to severe liver damage [94]. During acute MCMV infection, NK cells in the liver also produce IL-10 [95]. Although this cytokine does not contribute to viral control or the initiation of adaptive anti-viral immunity, it limits the magnitude of CD8 T cell responses and consequent pathology in mice lacking perforin [96]. In humans, expansion of CD56dim CD16+ NK cells expressing NKG2C has been noted in individuals with active CMV infection [97, 98]; these cells are maintained long term and can expand following exposure to CMV antigen, as noted in allo- geneic stem cell transplantation [99]. The role of these NK cells, referred to as “adaptive or memory-like” NK cells, remains largely unknown, and further investigation is required to determine how memory-like NK cells affect CMV infection and reactivation in organs like the liver.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the recently emerged virus at the centre of a global pandemic. SARS-CoV-2 infection primarily targets cells of the respiratory tract but virus has been detected in multiple organs, including the liver [100]. Furthermore, SARS-CoV-2 infection can have a series of extrapolmonary manifestations, including hepatobiliary damage (reviewed in [101]). Acute hepatitis has been reported [102, 103], and increased concentrations of enzymes associated with liver damage (AST, ALT) were found to correlate with the severity of COVID-19 disease [103–105]. COVID-19-associated complications have also been reported in a liver transplant patient, where infection appeared related to the virus being passed by a SARS-CoV-2-positive donor [106]. Enormous efforts have been directed to unravel the complexi- ties of protective versus pathogenic immune responses in the context of SARS-CoV-2 infection. However, current understanding of tissue-specific immunity in tissues such as the liver is still limited. Although tissue inflammation and increased frequencies of immune cells have been observed in livers of COVID patients, the potential contribution of IrNK or cNK cells to SARS-CoV-2 control and/or COVID-19 pathology remains unknown [107]. Analyses of circulating NK cells have revealed a reduction in both CD56bright and CD56dim NK cells in COVID-19 patients compared to healthy controls [108]. The remaining NK cells displayed a more activated phenotype but also appeared to upregulate markers associated with limiting NK cell function (NKG2A), and indeed NK cell effector functions were compromised in severely ill COVID-19 patients [108–110]. Interestingly, an enrichment of “adaptive” NK cells was also observed [108]. A reduction in circulating NK cells has also been reported in children infected by SARS-CoV-2 prompting investigators to suggest that NK cells might have been recruited to sites of infection to provide protective immu- nity [111]. Overall, NK cells clearly mount a response to SARS-CoV-2 infection, but similar to hepatitis virus infections, they might become dysfunctional during severe disease, and their role in organs like the liver requires further investigation.

In sum, the available evidence demonstrates that during viral infections, populations of NK cells that reside in or are recruited to the liver mediate a plethora of activities. These activities range from those that clearly favour health by providing either anti-viral protective immunity or limiting overt inflammation, to those that are highly pathogenic and contribute to tissue disruption, either directly or by favouring the pathological activities of other cell types. For these reasons, it is imperative to define the role of NK cells in viral infections so that appropriate interventions can be utilised.

**Fatty liver disease**

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is characterised by steatosis, the
accumulation of lipids, within hepatocytes. Progression of the disease can lead to non-alcoholic steatohepatitis (NASH) involving inflammation and fibrosis. Risk of liver cirrhosis and progression to HCC is increased following transition to NASH. Additionally, NAFLD is often associated with metabolic syndrome along with obesity, high blood pressure and type II diabetes. NAFLD can be controlled early through weight loss and lifestyle changes, but no other treatment is currently available, and the associated co-morbidities complicate treatment if disease progresses further to HCC. Alarmingly, as obesity increases in western nations, so does the frequency of NAFLD and NASH. Evidence from murine models of liver disease have implicated NK cells in disease progression to NASH. In these models, NK cell ligand expression is increased in the liver, thus promoting accumulation of NK cells [112, 113]. IL-15-based activation of NK cells has been shown to lead to NASH in the murine setting [114], but interestingly, NK cells have also been shown to prevent liver fibrosis [50, 115]. This is achieved both through NK cell influence on macrophage polarisation in the liver in an NKp46-dependent manner and via killing of HSCs by NK cells in an NKG2D-dependent manner [50, 115]. In humans, NKp46-based protection against fibrosis has also been described, though in the setting of HCV [116]. Increased expression of the activating receptor NKG2D by circulating NK cells has been observed in NASH patients [117], and it is possible that this results in increased HSC killing in the mouse model. Diedrich et al observed a negative correlation between fibrosis and NK cell frequency in the liver, indicating an involvement of NK cells in preventing fibrosis [118]. Interestingly, lower NKG2D expression was observed in circulating NK cells of NAFLD patients compared to healthy individuals, and a similar trend was seen in NK cells within the liver [118]. The downregulation of NKG2D in the context of NAFLD may give rise to a more pro-fibrotic NK cell population, thus contributing to worsening liver disease and fibrosis. It is possible that changes such as this are mediated by metabolic changes. Indeed, the function of NK cells has been shown to be reduced in obese patients due to excessive lipid uptake [119]. NK cells are also known to produce IL-22 following activation [58]. In mice, IL-22 has been shown to have an anti-fibrotic effect [120]; however, IL-22 has also been demonstrated to have a pro-fibrogenic role in a chronic HBV model [121], further confusing matters. Altogether, these data indicate that NK cells have a complex role in the pathogenesis of NAFLD. While NK cells appear to have a role in preventing fibrosis, changes in NKG2D-expression by NK cells accompany increasing fibrosis. Furthermore, pro-inflammatory NK cell signalling may promote NAFLD progression to NASH, and the role of IL-22 in fibrosis is still not fully understood.

**NK cell based/targeted therapies for liver disease**

As NK cells play an important role in liver disease, they also have the potential to serve as a therapeutic target for these diseases. Modulation of existing NK cells can be achieved through cytokine stimulation or antibody treatment targeting

---

**Fig. 5 NK cell targeted therapies.** A virally infected cell A inhibiting an NK cell via signalling through NKG2A or B being killed due to blockade of inhibition with anti-NKG2A monoclonal antibody. C A CAR NK cell recognising an overexpressed surface protein on an infected cell via an engineered CAR receptor causing activation and subsequent killing. Created with BioRender.com
either inhibiting or activating NK cell receptors. Indeed, NK cells respond to a wide array of cytokines including type I IFNs, IFNγ, IL-2, IL-12, IL-15 and IL-18. NK cells from IFNα-treated HCV patients have been shown to have increased killing of HSCs in vitro, which has been linked to a reduction in liver fibrosis [49]. IFNα treatment was shown in early studies to reduce fibrosis in HCV patients [122, 123] though more recent data indicates that it provides no benefit [124]. Of note, treatment of HCV with direct DAAs shows long-term decrease in liver fibrosis, indicating that viral clearance is sufficient for improvement [125]. Although DAAs now offer effective treatment against HCV, the same is not true for HBV. Treatment with a TLR8 agonist can indirectly activate NK cells via dendritic cell-produced cytokines, and this may prove to be an effective way to combat HBV [126].

Checkpoint blockade has transformed the treatment of melanoma by reversing exhaustion and restoring effective anti-cancer activity of T cells. As with T cells, NK cells also express inhibitory receptors such as KIRs, NKG2A and TIGIT on their cell surface to quell unwanted activation. NK cells expressing inhibitory NKG2A have been shown to be increased in chronic HBV infection [127]. Interestingly, ex vivo blockade of NKG2A increased NK cell cytotoxicity, and blockade in a mouse HBV model improved viral clearance [127]. NKG2A blockade in a mouse HCV model was also shown to improve NK cell cytotoxicity [88]. These results indicate that checkpoint blockade of NK cells may be a viable anti-viral treatment in chronic liver infection (Fig. 5). Blockade of TIGIT [128] and TIM3 [129], inhibitory molecules expressed by NK cells, is known to improve NK cell cytotoxicity against tumours. These molecules are also highly expressed on NK cells in HCV patients with advanced liver fibrosis, indicating that blockade, in this instance, may restore NK cell functionality and protection [130].

Genetically modified NK cells with chimeric antigen receptors (CAR NK cells) targeting HCC are currently being tested in multiple clinical trials, as are bi- and tri-specific antibodies designed to activate NK cells at the same time as targeting them to tumour cells [131, 132]. CARs are receptors with a specific, often antibody-derived, binding region with downstream signalling domains designed to enhance activation in the context of a specific target ligand [133] (Fig. 5). CAR NK cells and bi- and tri-specific antibodies all rely on the overexpression of specific ligands on cancerous cells. Whether these technologies can be re-purposed in the context of viral infections or liver fibrosis is yet to be seen and would rely on specific surface expression of otherwise rare ligands on target cells.

**Conclusion**

NK cells are present in high abundance in the liver and thus have a large impact on the immune environment in the organ. They provide potent pro-inflammatory and cytotoxic defence against viral challenge, but dysregulation of the NK-cell response can lead to chronic inflammation and disease. Despite the importance of NK cells in the liver, much is still unknown about the exact mechanisms by which they contribute to different liver diseases, and more study is needed to understand under which circumstances NK cell subpopulations can promote or reduce liver inflammation. Discovery of distinct populations of NK cells within the liver furthermore suggests a heterogeneity in their roles. Better understanding of the specific function of different lrNK cells and cNK cells present in the liver may help to elucidate the importance of these subsets in different disease settings. Indeed, the more is known about the role of NK cells in liver disease, the more opportunity there is for targeted manipulation of these cells to ultimately improve patient outcomes.

**Author contribution** All authors contributed equally.

**Funding** Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) through the SFB841.

**Availability of data and material** N/A.

**Code availability** N/A.

**Declarations**

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in accordance with the Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Freitas-Lopes M, Mafra K, David B, Carvalho-Gontijo R, Menezes G (2017) Differential location and distribution of hepatic immune cells. Cells 6:48. https://doi.org/10.3390/cells6040048
2. Tanimine N, Tanaka Y, Abe T, Piao J, Chayama K, Oldan H (2016) Functional behavior of Nkp46-positive intrahepatic natural killer cells against hepatitis C virus reinfection after liver transplantation. Transplantation 100:355–364. https://doi.org/10.1097/TP.0000000000001031
and NK cells. J Exp Med 205:233–244. https://doi.org/10.1084/jem.20072195
32. Lassen MG, Lukens JR, Dolina JS, Brown MG, Hahn YS (2010) Intrahepatic IL-10 maintains NKG2A+ Ly49 – liver NK cells in a functionally hyporesponsive state. J Immunol 184:2693–2701. https://doi.org/10.4049/jimmunol.0901362
33. Chong WP, Zhou J, Law HKW, Tu W, Lau YL (2010) Natural killer cells become tolerogenic after interaction with apoptotic cells. Eur J Immunol 40:1718–1727. https://doi.org/10.1007/ej.20093768
34. Zhou J, Peng H, Li K, Qu K, Wang B, Wu Y, Ye L, Dong Z, Wei H, Sun R, Tian Z (2019) Liver-resident NC cells control antiviral activity of hepatic T cells via the PD-1–PD-L1 axis. Immunity 50: 403–417.e4. https://doi.org/10.1016/j.immuni.2018.12.024
35. Nabekura T, Riggan L, Hildeadh ET, O’Sullivan TE, Shibuya A (2020) Type 1 innate lymphoid cells protect mice from acute liver injury via interferon-γ secretion for upregulating Bel-3 expression in hepatocytes. Immunity 52:96–108.e9. https://doi.org/10.1016/j.immuni.2019.11.004
36. Sun R, Gao B (2004) Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-γ). Gastroenterology 127:1525–1539. https://doi.org/10.1016/j.gastro.2004.08.055
37. Horras CJ, Lamb CL, Mitchell KA (2011) Regulation of hepatoocyte fate by interferon-γ. Cytokine Growth Factor Rev 22:35–43. https://doi.org/10.1016/j.cytogfr.2011.01.001
38. Alizadeh AHM, Shahnaiz A, Rasoulzadeh A, Shams E, Mohammadi M, Darabi F, Beldad M (2012) Characteristic findings of primary sclerosing cholangitis on endoscopic retrograde cholangiography: Which is the Most Common Finding? Clin Med Insights Gastroenterol 5:CGast.S7850. https://doi.org/10.4137/CGast.S7850
39. Chuang YH, Lian ZX, Tsuneyama K et al (2006) Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun 26:232–240. https://doi.org/10.1016/j.jaut.2006.04.001
40. Shimoda S, Harada K, Niiro H et al (2011) Interaction between toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology 53:1270–1281. https://doi.org/10.1002/hep.24194
41. Shimoda S, Hisamoto S, Harada K, Iwasaka S, Chong Y, Nakamura M, Bekki Y, Yoshizumi T, Shirabe K, Ikegami T, Maehara Y, He XS, Gershwin ME, Akashi K (2015) Natural killer cells regulate T cell immune responses in primary biliary cirrhosis. Hepatology 62:1817–1827. https://doi.org/10.1002/hep.28122
42. Hydes TJ, Blunt MD, Natej L, Vallejo AE, Seunois G, Wang A, Vijayanand P, Polak ME, Khakhoo SI (2019) Constitutive activation of natural killer cells in primary biliary cholangitis. Front Immunol 10:1–12. https://doi.org/10.3389/fimmu.2019.02633
43. Weismüller TJ, Strassburg CP, Trivedi PJ et al (2017) Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 152: 1975–1984.e8. https://doi.org/10.1053/j.gastro.2017.02.038
44. Lunder AK, Hov JR, Borthnne A, Gleditsch J, Johannesen G, Tveit K, Viktil E, Henriksen M, Hovde Ø, Huppertz-Hauss G, Haie O, Hotvik ML, Monstad I, Solberg IC, Jahnsen J, Karlsen TH, Moum B, Vatn M, Negård A (2016) Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology 151: 660–669.e4. https://doi.org/10.1016/j.gastro.2016.06.021
45. Karlsen TH, Boberg KM, Olsson M, Sun JY, Senitzer D, Bergquist A, Schrumple E, Thorsby E, Lie BA (2007) Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol 46:899–906. https://doi.org/10.1016/j.jhep.2007.01.032
46. Berglin L, Bergquist A, Johansson H, Glaumann H, Jorns C, Lunemann S, Wedemeyer H, Ellis EC, Björkström NK (2014) In situ characterization of intrahepatic non-parenchymal cells in PSC reveals phenotypic patterns associated with disease severity. PLoS One 9:1–11. https://doi.org/10.1371/journal.pone.0105375
47. Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, Horani A, Nassar M, Friedman SL, Safadi R (2006) Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 45:60–71. https://doi.org/10.1016/j.jhep.2005.12.025
48. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B (2006) Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130:435–452. https://doi.org/10.1053/j.gastro.2005.10.055
49. Glässner A, Eisenhardt M, Krämer B, Körner C, Coenen M, Sauerbruch T, Spengler U, Nattermann J (2012) NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-,. FasL- and NKG2D-dependent manner. Lab Invest 92:967–977. https://doi.org/10.1038/labinvest.2012.54
50. Gur C, Doron S, Kfir-Erenfeld S, Horwitz E, Abu-tair L, Safadi R, Mandelboim O (2012) NKP46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut 61:885–893. https://doi.org/10.1136/gutjnl-2011-301400
51. Langeneckert AE, Lunemann S, Martinus G, Glaumann H, Jorns C, Ostermann S, Tietze E, Oldhafer KJ, Schramm C, Alfeldt M (2019) CCL21-expression and accumulation of CCR7+ NK cells in livers of patients with primary sclerosing cholangitis. Eur J Immunol 49:758–769. https://doi.org/10.1002/eji.201847965
52. Grant AJ, Goddard S, Ahmed-Choudhury J, Reynolds G, Jackson DG, Briskin M, Wu L, Hübser SG, Adams DH (2002) Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am J Pathol 160:1445–1455. https://doi.org/10.1016/S0002-9440(01)68250-7
53. Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, Lohse AW, Montano-Loza AJ (2018) Autoimmune hepatitis. Nat Rev Dis Prim 4:1–22. https://doi.org/10.1038/nrdp.2018.17
54. Strassburg CP, Obermayer-Straub P, Alex B, Durazzo M, Rizzetto M, Tykay RH, Manns MP (1996) Autoantibodies against GSH-S-transferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 111:1576–1586. https://doi.org/10.1016/S0016-5085(96)70020-3
55. Martini E, Abuaf N, Cavalli F, Durand VÉR, Johanan C, Homberg JC (1998) Antibody to liver cytosol (anti-CL1) in patients with autoimmune chronic hepatitis type 2. Hepatology 8:1662–1666. https://doi.org/10.1002/hep.1840080632
56. Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Lévy VG, Grippon P, Opolon P, Bernau J, Benhamou JP, Alagille D (1987) Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology 7:1333–1339. https://doi.org/10.1002/hep.1840070626
57. Johnson G, Holborow E, Glynn L (1965) Antibody to smooth muscle in patients with liver disease. Lancet 286:878–879. https://doi.org/10.1016/S0140-6736(65)92956-5
58. Puustinen L, Barner-Rasmussen N, Pukkala E, Färkkilä M (2019) Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: a nationwide register-based cohort study in Finland. Dig Liver Dis 51:1294–1299. https://doi.org/10.1016/j.dld.2019.01.015
64. Jeffery HC, Braitch MK, Bagnall C, Hodson J, Jeffery LE, Zhao J, Li Y, Jin L, Zhang S, Fan R, Sun Y, Zhou C, Shang Q, Li Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Zheng M, Sun R, Wei H, Tian Z (2016) NK cells help induce anti-hepatitis viruses: summary of a workshop. In: Nishioka K, Suzuki World Heal Organ Springer Japan, Tokyo, pp 47–1137. https://doi.org/10.1038/s41590-019-0448-4

65. Xiao F, Ai G, Yan W, Xu Z, Wei H, Sun R, Hu Z, Gao B, Tian Z (2004) Involvement of natural killer cells in PolyI:C-induced liver injury. J Hepatol 41: 966–973. https://doi.org/10.1016/j.jhep.2004.08.021

66. Jeffery HC, Braitch MK, Bagnall C, Hodson J, Jeffery LE, Wawman RE, Wong LL, Birtwistle J, Bartlett H, Lohse AW, Hirschfeld GM, Dyson J, Jones D, Hubscher SG, Klenerman P, Adams DH, Oo YH (2018) Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis. Hepatol Commun 2:421–436. https://doi.org/10.1002/hepc.24163

67. WHO (2017) Executive summary - global hepatitis report, 2017. World Heal Organ

68. Zhao J, Li Y, Jin L, Zhang S, Fan R, Sun Y, Zhou C, Shang Q, Li W, Zhang Z, Wang FS (2012) Natural killer cells are characterized by the concomitantly increased interferon-γ and cytotoxicity in acute resolved hepatitis B patients. PLoS One 7:e49135. https://doi.org/10.1371/journal.pone.0049135

69. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Orlandini A, Sacchelli L, Missale G, Ferrari C, Khakoo SI (2010) Activation of natural killer cells to control HCV replication in cell culture. Gastroenterology 139:1366–1371.e3. https://doi.org/10.1053/j.gastro.2010.07.019

70. Yu W-H, Cosgrove C, Berger CT et al (2018) ADCC-mediated CD56dim NK cell responses are associated with early HBsAg clearance in acute HBV infection. Pathog Immun 3.2. https://doi.org/10.20411/pai.v3i1.288

71. Zheng M, Sun R, Wei H, Tian Z (2016) NK cells help induce anti-hepatitis B virus CD8+ T cell immunity in mice. J Immunol 196: 4122–4131. https://doi.org/10.4049/jimmunol.1500846

72. Lunemann S, Malone DF, Hengst J, Port K, Grabowski J, Dettering K, Markova A, Bremer B, Schlaphoff V, Cornberg M, Manns MP, Sandberg JK, Ljangren HG, Björkström NK, Wedemeyer H (2014) Compromised function of natural killer cells in chronic hepatitis B and chronic hepatitis C virus infection. J Infect Dis 209:1362–1373. https://doi.org/10.1093/infdis/jit561

73. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D, de Filippi F, Bruno S, Mondelli MU (2009) Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137:1151–1160.e7. https://doi.org/10.1053/j.gastro.2009.05.047

74. Wijaya RS, Read SA, Schibeci S, Han S, Azardaryani MK, Poorten D, Lin R, Yuen L, Lam V, Douglas MW, George J, Ahlenstiel G (2021) Expansion of dysfunctional CD56+CD16+ NK cells in chronic hepatitis B patients. Liver Int 41:969–981. https://doi.org/10.1111/liv.14784

75. Peppa D, Micco L, Javaid A, Kennedy PTF, Schurich A, Dunn C, Pallani C, Ellis G, Khanna P, Dusheiko G, Gilson RJ, Maini MK (2010) Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 6:e1001227. https://doi.org/10.1371/journal.ppat.1001227

76. Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z, Wei H (2012) TGF-β1 down-regulation of NKGD2/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog 8:e1002594. https://doi.org/10.1371/journal.ppat.1002594

77. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertolotti A, Maini MK (2007) Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 204:667–680. https://doi.org/10.1084/jem.20061287

78. Jiang Y, Qin S, Wei X, Liu X, Guan J, Zhu H, Chang G, Chen Y, Lu H, Qian J, Wang Z, Shen M, Lin X (2021) Highly activated TRAIL+ CD56bright NK cells are associated with the liver damage in HBV-LC patients. Immunol Lett 232:9–19. https://doi.org/10.1016/j.imlet.2020.12.008

79. Peppa D, Gill US, Reynolds G, Eason NJW, Pallett LJ, Schurich A, Micco L, Nebbia G, Singh HD, Adams DH, Kennedy PTF, Maini MK (2013) Up-regulation of a death receptor renders anti-viral T cells susceptible to NK cell-mediated deletion. J Exp Med 210:99–114. https://doi.org/10.1084/jem.20121172

80. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgarten M, Cox S, Little AM, Alexander GJ, Cramp ME, O’Brien SJ, Rosenberg WM, Thomas DL, Carrington M (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (80-) 305:872–874. https://doi.org/10.1126/science.1097670

81. Lunemann S, Schönbel A, Kah J, Fitte P, Hölzemer A, Langeneckert AE, Hess LU, Poch T, Manns G, Garcia-Beltran WF, Körner C, Ziegler AE, Richert L, Oldhafer KJ, Schulze zur Wiesch J, Schramm C, Dandi M, Herker E, Altfeld M (2018) Interactions between KIR3DS1 and HLA-F activate natural killer cells to control HCV replication in cell culture. Gastroenterology 155:1366–1371.e3. https://doi.org/10.1053/j.gastro.2018.07.019

82. Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, Ahmed P, Missale G, Ferrari C, Khakoo SI (2010) Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 138:1536–1545. https://doi.org/10.1053/j.gastro.2010.01.006

83. Hengst J, Klein AL, Lunemann S, Dettering K, Hardtke S, Falk CS, Manns MP, Cornberg M, Schlaphoff V, Wedemeyer H (2018) Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection. J Viral Hepat 26:jvh.13050. https://doi.org/10.1111/jvh.13050

84. Alter G, Jost S, Rihn S, Reyor LL, Nolan BE, Ghebremichael M, Bosch R, Altfeld M, Lauer GM (2011) Reduced frequencies of NKp30+NKp46+, CD16+, and NKGD2+ NK cells in acute HCV infection may predict viral clearance. J Hepatol 55:278–288. https://doi.org/10.1016/j.jhep.2010.11.030
85. Golden-Mason L, Madrigal-Estebas L, McGrath E, Conroy MJ, Ryan EJ, Hegarty JE, O’Farrelly C, Doherty DG (2008) Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 57:1121–1128. https://doi.org/10.1136/gut.2007.130963

86. Ahlenstiel G, Titerence RH, Koh C, Edlich B, Feld JJ, Rotman Y, Ghany MG, Hoofnagle JH, Liang TJ, Heller T, Rehermann B (2010) Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon–α-dependent manner. Gastroenterology 138:325–335.e2. https://doi.org/10.1053/j.gastro.2009.08.066

87. Jinushi M, Takehara T, Tatsumi T, Kanto T, Miyagi T, Suzuki T, Kanazawa Y, Hiramatsu N, Hayashi N (2004) Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell–induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 173:6072–6081. https://doi.org/10.4049/jimmunol.173.10.6072

88. Zhang C, Wang X, Li S, Twelkmeyer T, Wang WH, Zhang SY, Shi L, Wang F-S (2020) Liver injury in COVID-19: a review. J Hepatol 73:446–455. https://doi.org/10.1016/j.jhep.2020.09.010

89. Foley B, Cooley S, Vemieris MR, Pitt M, Curtisinger J, Luo X, Lopez-Vergés S, Lanier LL, Weisdorf D, Miller JS (2012) Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119:2665–2674. https://doi.org/10.1182/blood-2011-10-386985

90. Puelles VG, Lütgehetmann M, Lindemeyer MT, Sperhake JP, Ganem D, Winkler ML, Altmann M, Almon C, Elaman C, El-Sherwani H, Hiramatsu N, Hayashi N (2004) Multifocal viral infection and histological alterations of COVID-19. J Med Virol 76:739–748. https://doi.org/10.1002/jmv.20137

91. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, B-dollar B, Ashuwal A, Nussel J, Dan Y, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Baker KA, Leon MB, Krumholz HM, Uriel N, Mera MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikjian JP, Landry DW (2020) Extrapolatory manifestations of COVID-19. Nat Med 26:1017–1032. https://doi.org/10.1038/s41591-020-0968-3

92. Yao X, Ye F, Zhang M, Cui H, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71:732–739. https://doi.org/10.1093/cid/ciaa237

93. Zhang C, Shi L, Wang F-S (2020) Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 5:428–430. https://doi.org/10.1016/S2468-1253(20)30057-1

94. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang J, Jiang R, Gao Z, Jia Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

95. Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, Li L, Shan H, Lei CL, Hui DSC, du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei I, Liu Y, Hu YH, Peng P, Wang J, Yang JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720. https://doi.org/10.1056/NEJMoa2002032

96. Lagana SM, De Michele S, Lee MJ et al (2020) COVID-19–associated hepatitis complicating recent living donor liver transplantation. Arch Pathol Lab Med 144:929–932. https://doi.org/10.5858/arpa.2020-0186-SA

97. Wang C, Xu J, Wang S, Pan S, Pan Z, Shang J, Han Y, Huang M, Wu D, Yang Y, Wang X, Yang Y, Shu T, Zou X, Li R, Luo Y, Yao R, Wang Y, Qiu Y, Wang Y, Zhang DY, Yao Q, Yan Y, Zhou X, Sha Y (2020) Imaging mass cytometric analysis of postmortem samples provides new insights into COVID-19-related liver injury. Sci Immunol 5:eabd6832. https://doi.org/10.1126/sciimmunol.abd6832

98. Ali AK, Komal AK, Almutairi SM, Lee S-H (2019) Natural killer cell–derived IL-10 prevents liver damage during sustained murine cytomegalovirus infection. Front Immunol 10:1–14. https://doi.org/10.3389/fimmu.2019.02688

99. Ali AK, Komal AK, Almutairi SM, Lee S-H (2019) Natural killer cell–derived IL-10 prevents liver damage during sustained murine cytomegalovirus infection. Front Immunol 10:1–14. https://doi.org/10.3389/fimmu.2019.02688

100. Liu M, Xiao Y, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jia Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

101. Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, Li L, Shan H, Lei CL, Hui DSC, du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei I, Liu Y, Hu YH, Peng P, Wang J, Yang JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720. https://doi.org/10.1056/NEJMoa2002032

102. Lagana SM, De Michele S, Lee MJ et al (2020) COVID-19–associated hepatitis complicating recent living donor liver transplantation. Arch Pathol Lab Med 144:929–932. https://doi.org/10.5858/arpa.2020-0186-SA

103. Wang C, Xu J, Wang S, Pan S, Pan Z, Shang J, Han Y, Huang M, Wu D, Yang Y, Wang X, Yang Y, Shu T, Zou X, Li R, Luo Y, Yao R, Wang Y, Qiu Y, Wang Y, Zhang DY, Yao Q, Yan Y, Zhou X, Sha Y (2020) Imaging mass cytometric analysis of postmortem samples provides new insights into COVID-19-related liver injury. Sci Immunol 5:eabd6832. https://doi.org/10.1126/sciimmunol.abd6832
109. Zheng M, Gao Y, Wang G, et al (2020) Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 17:533–535. https://doi.org/10.1038/s41423-020-04002-2

110. Osman M, Faridi RM, Stigli W, Shahani-Rad MT, Dharmani-Khan P, Parker A, Kalra A, Tripathi MB, Storek J, Cohen Tervaert JW, Khan FM (2020) Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19. Blood Adv 4:5035–5039. https://doi.org/10.1182/bloodadvances.2020002650

111. Neeland MR, Bannister S, Clifford F, Dohle K, Mulholland K, Sutton P, Curtis N, Steer AC, Brunner DP, Crawford NW, Tosif S, Saffery R (2021) Innate immune profiles during the acute and convalescent phase of SARS-CoV-2 infection in children. Nat Commun 12:1084. https://doi.org/10.1038/s41467-021-21414-x

112. Gomez-Santos L, Luka Z, Wagner C, Fernandez-Alvarez S, Lu SC, Mato JM, Martinez-Chantar ML, Beraza N (2012) Inhibition of natural killer cell killers protects the liver against acute injury in the absence of glycine N-methyltransferase. Hepatology 56:747–759. https://doi.org/10.1002/hep.25694

113. Kahraman A, Schlattian M, Kocabayoglu B, Yildiz-Meziletoglu S, Schlenstad M, Chen YG, Rolra-Pleszcynski M, Menendez A, Ilamburger S, Ramanathan S (2016) Interleukin-15-mediated inflammation promotes non-alcoholic fatty liver disease. Cytokine 82: 102–111. https://doi.org/10.1016/j.cyto.2016.01.020

114. Cepero-Donates Y, Lacraz G, Ghobadi F, Rakotoarivelo V, Orkhis Gene Ther. https://doi.org/10.1038/s41434-021-00246-w

115. Krämer B, Körner C, Kebschull M, Glässner A, Eisenhardt M, Diedrich T, Kummer S, Galante A, Drolz A, Schlicker V, Lohse NAFLD. PLoS One 15:1. https://doi.org/10.1371/journal.pone.0230307

116. Leitinger N, Hahn YS (2016) NKp46+ natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice. Hepatology 63:799–812. https://doi.org/10.1002/hep.28389

117. Stiglund N, Strand K, Cormilitl M, Stål P, Thorell A, Zimmer CL, Näsund E, Karlsgen S, Nilsson H, Melfgren G, Ferno J, Hagström H, Bjärkström NK (2019) Retained NK cell phenotype and functionality in non-alcoholic fatty liver disease. Front Immunol 10:1–13. https://doi.org/10.3389/fimmu.2019.01255

118. Diedrich T, Kummer S, Galante A, Drozla A, Schlicker V, Lohse AW, Klueve J, Eberhard JM, Schulze zur Wiesch J (2020) Characterization of the immune cell landscape of patients with NAFLD. PLoS One 15:1–16. https://doi.org/10.1371/journal.pone.0230307

119. Michelel X, Dyck L, Hagan A, Lothf RM, Duquette D, Wei K, Beyer S, Tavakkoli A, Foley C, Donnelly R, O’Farrel C, Raverdeau M, Vernon A, Petee W, O’Shea D, Nikolajczyk BS, Mills KHG, Brenner MB, Finlay D, Lynch L (2018) Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol 19:1330–1340. https://doi.org/10.1038/s41590-018-0251-7

120. Thakur A, Pedersen LE, Jungersen G (2012) Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 30:4907–4920. https://doi.org/10.1016/j.vaccine.2012.05.049

121. Zhao J, Zhang Z, Luan Y, Zou Z, Sun Y, Li Y, Jin L, Zhou C, Fu J, Gao B, Fu Y, Wang FS (2014) Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology 59:1331–1342. https://doi.org/10.1002/hep.26916

122. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujisawa Y, Yoshida H, Omata M (2000) Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132:517–524. https://doi.org/10.7326/0003-4819-132-7-200004040-00002

123. Guerret S, Desmouliere A, Chossegros P, Costa AMA, Badic D, Triepo C, Grimaud JA, Chevalier M (1999) Long-term administration of interferon-α in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years. J Viral Hepat 6: 125–133. https://doi.org/10.1046/j.1365-2893.1999.00148.x

124. Di Bisceglie AM, Shiffman ML, Everson GT et al (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359:2429–2441. https://doi.org/10.1056/nejmoa0706715

125. Laursen TL, Siggaard CB, Kazakova K, Sandahl TD, Mellor HJ, Tarp B, Kristensen LH, Laursen AL, Leutsher P, Gronkrek H (2020) Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting anti-viral therapy of chronic hepatitis C. J Viral Hepat 27:28–35. https://doi.org/10.1111/jvh.13204

126. Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan-Garcia A, To N, Hong M, Chia A, Gill US, Kennedy PT, Tan KC, Lee KH, de Libero G, Gehring AJ, Willberg CB, Klenerman P, Bertoletti A (2014) Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog 10:1–13. https://doi.org/10.1371/journal.ppat.1004210

127. Wei H, Li F, Wei H et al (2013) Blocking the natural killer cell inhibitor receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. Gastroenterology 144:392–401. https://doi.org/10.1053/j.gastro.2012.10.039

128. Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu P, Peng H, Wei H, Sun R, Tian Z (2018) Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 19:723–732. https://doi.org/10.1038/s41590-018-0132-0

129. Xu L, Huang Y, Tan L, Yu W, Chen D, Lu CC, He J, Wu G, Liu X, Zhang Y (2015) Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol 29:635–641. https://doi.org/10.1016/j.intimp.2015.09.017

130. Okwor CIA, Oh JS, Crowley AM, Cooper CL, Lee SH (2020) Expression of inhibitory receptors on T and NK cells defines immunological phenotypes of HCV patients with advanced liver fibrosis. iScience 23:101531. https://doi.org/10.1016/j.isci.2020.101513

131. Felices M, Kodal B, Hinderle P, Kaminski MF, Cooley S, Weisendorf DJ, Vallera DA, Miller JS, Bachanova V (2019) Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. Blood Adv 3:897–907. https://doi.org/10.1182/bloodadvances.2018029371

132. Albinger N, Hartmann J, Ulrich E (2021) Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. https://doi.org/10.1038/s41434-021-00246-w

133. Pfefferle A, Huntington ND (2020) You have got a fast CAR: chimeric antigen receptor NK cells in cancer therapy. Cancers (Basel) 12:706. https://doi.org/10.3390/cancers12030706

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.